Biomarkers in acute myocardial infarction

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Chan, Daniel ^a   Ng, Leong L ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Leicester National Institute for Health Research Cardiovascular Biomedical Research Unit ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL PRO ENDOTHELIN 1; COPEPTIN; ENDOTHELIN 1; GELATINASE A; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; HEART TYPE FATTY ACID BINDING PROTEIN; MID REGIONAL PRO ADRENOMEDULLIN; MID REGIONAL PRO ATRIAL NATRIURETIC PEPTIDE; MYELOPEROXIDASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN ST2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; DEATH; DIAGNOSTIC VALUE; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MECHANICAL STRESS; MORTALITY; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN STABILITY; REVIEW; SCORING SYSTEM; THORAX PAIN; BLOOD; BLOOD ANALYSIS; HEART INFARCTION;

BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS;

EID: 77954377464     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-34     Document Type: Review

References (114)

1. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000, 355:688-700. 10.1016/S0140-6736(99)11181-4, 10703800.
2. Biological Markers - MeSH Result. , http://www.ncbi.nlm.nih.gov/mesh/68015415?ordinalpos=1&itool=EntrezSystem2.PEntrez.Mesh.Mesh_ResultsPanel.Mesh_RVDocSum
3. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195. 10.1016/j.jacc.2007.09.011, 18036459.
4. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362. 10.1161/CIRCULATIONAHA.104.482570, 16702488.
5. WHO Expert Committee on Diabetes Mellitus: Second report. World Health Organ Tech Rep Ser 1980, 646:1-80.
6. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969. 10.1016/S0735-1097(00)00804-4, 10987628.
7. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342-1349. 10.1056/NEJM199610313351802, 8857017.
8. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Münzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009, 361:868-877. 10.1056/NEJMoa0903515, 19710485.
9. Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 2004, 16:348-355. 10.1111/j.0953-8194.2004.01172.x, 15089973.
10. Goldsmith SR. Vasopressin as Vasopressor. American Journal of Medicine 1987, 82:1213-1219. 10.1016/0002-9343(87)90228-2, 3300305.
11. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999, 195:93-98. 10.1023/A:1006980517557, 10395073.
12. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, . Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971. 10.1001/jama.291.16.1963, 15113814, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.
13. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006, 47:1615-1621. 10.1016/j.jacc.2005.11.071, 16630999.
14. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009, 54:60-68. 10.1016/j.jacc.2009.01.076, 19555842.
15. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schwarz S, Hasibeder WR, Friesenecker BE, Dunser MW. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006, 91:4381-4386. 10.1210/jc.2005-2830, 16940457.
16. Glatz JF, Luiken JJ, van Nieuwenhoven FA, Van der Vusse GJ. Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandins Leukot Essent Fatty Acids 1997, 57:3-9. 10.1016/S0952-3278(97)90485-3, 9250601.
17. Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 1988, 961:148-152.
18. Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A, Renneberg R. A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol 2004, 93:388-397. 10.1007/s00392-004-0080-6, 15160274.
19. Chen L, Guo X, Yang F. Role of heart-type fatty acid binding protein in early detection of acute myocardial infarction in comparison with cTnI, CK-MB and myoglobin. J Huazhong Univ Sci Technolog Med Sci 2004, 24:449-451. 459.
20. Body R. Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Bet 2. Heart Fatty Acid binding protein for rapid diagnosis of acute myocardial infarction in the emergency department. Emerg Med J 2009, 26:519-522. 10.1136/emj.2009.076182, 19546277.
21. O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MS. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006, 114:550-557. 10.1161/CIRCULATIONAHA.106.641936, 16880323.
22. Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, Hall AS. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 2007, 50:2061-2067. 10.1016/j.jacc.2007.08.021, 18021874.
23. de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005, 26:865-872. 10.1093/eurheartj/ehi187, 15764619.
24. Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald E. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol 2002, 90:303-305. 10.1016/S0002-9149(02)02468-2, 12127617.
25. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000, 101:2557-2567.
26. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003, 163:2345-2353. 10.1001/archinte.163.19.2345, 14581255.
27. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998, 339:321-328. 10.1056/NEJM199807303390507, 9682046.
28. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021. 10.1056/NEJMoa011053, 11586953.
29. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996, 27:1656-1661. 10.1016/0735-1097(96)00067-8, 8636550.
30. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996, 93:1963-1969.
31. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004, 42:942-944. 10.1515/CCLM.2004.153, 15387447.
32. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate J, Wu AH, Ler R, Apple FS. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008, 54:619-621. 10.1373/clinchem.2007.097998, 18310156.
33. Lorgis L, Zeller M, Dentan G, Sicard P, Buffet P, L'Huillier I, Beer JC, Vincent-Martin M, Makki H, Gambert P, Cottin Y. Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. BMJ 2009, 338:b1605. 10.1136/bmj.b1605, 2678205, 19420032.
34. Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond) 2009, 117:31-39. 10.1042/CS20080419, 19170658.
35. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003, 41:1264-1272. 10.1016/S0735-1097(03)00168-2, 12706919.
36. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003, 42:1909-1916. 10.1016/j.jacc.2003.07.015, 14662251.
37. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002, 106:2913-2918. 10.1161/01.CIR.0000041661.63285.AE, 12460871.
38. Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2004, 25:859-866. 10.1016/j.ehj.2004.03.004, 15140534.
39. Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008, 94:40-43. 10.1136/hrt.2006.108985, 17488769.
40. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 97:1921-1929.
41. Squire IB, O'Brien RJ, Demme B, Davies JE, Ng LL. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond) 2004, 107:309-316. 10.1042/CS20040087, 15182235.
42. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236. 10.1373/clinchem.2003.021204, 14709661.
43. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004, 50:1576-1588. 10.1373/clinchem.2004.032490, 15265819.
44. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008, 51:1857-1864. 10.1016/j.jacc.2008.01.041, 18466800.
45. Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, Chen Y, Zhang Y, Yang X. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 2005, 97:821-828. 10.1161/01.RES.0000185833.42544.06, 16151019.
46. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007, 115:962-971. 10.1161/CIRCULATIONAHA.106.650846, 17283261.
47. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007, 116:1540-1548. 10.1161/CIRCULATIONAHA.107.697714, 17848615.
48. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007, 28:2858-2865. 10.1093/eurheartj/ehm465, 17977844.
49. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009, 30:1057-1065. 10.1093/eurheartj/ehn600, 19168526.
50. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966. 10.1161/01.CIR.0000038705.69871.D9, 1460012, 12460879.
51. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190. 10.1161/01.CIR.0000127958.21003.5A, 15117853.
52. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549. 10.1172/JCI30634, 1865027, 17492053.
53. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471. 10.1126/science.1411543, 1411543.
54. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117:1936-1944. 10.1161/CIRCULATIONAHA.107.728022, 18378613.
55. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691. 10.1161/CIRCHEARTFAILURE.109.873240, 19919994.
56. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sugiyama Y. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001, 164:277-281.
57. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001, 284:1104-1108. 10.1006/bbrc.2001.5090, 11414697.
58. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research. J Am Coll Cardiol 2008, 52:1466-1467. 10.1016/j.jacc.2008.07.045, 19017514.
59. Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 2007, 154:736-742. 10.1016/j.ahj.2007.06.016, 17893002.
60. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415. 10.1038/332411a0, 2451132.
61. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989, 86:2863-2867. 10.1073/pnas.86.8.2863, 287019, 2649896.
62. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995, 92:357-363.
63. Kurihara H, Yamaoki K, Nagai R, Yoshizumi M, Takaku F, Satoh H, Inui J, Yazaki Y. Endothelin: a potent vasoconstrictor associated with coronary vasospasm. Life Sci 1989, 44:1937-1943. 10.1016/0024-3205(89)90406-2, 2661945.
64. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989, 161:562-567. 10.1016/0006-291X(89)92636-3, 2660789.
65. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991, 18:38-43. 10.1016/S0735-1097(10)80214-1, 2050938.
66. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993, 125:667-672. 10.1016/0002-8703(93)90155-3, 8438694.
67. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560. 10.1006/bbrc.1993.1451, 8387282.
68. Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 1994, 201:1160-1166. 10.1006/bbrc.1994.1827, 8024557.
69. Takahashi K, Satoh F, Hara E, Sone M, Murakami O, Kayama T, Yoshimoto T, Shibahara S. Production and secretion of adrenomedullin from glial cell tumors and its effects on cAMP production. Peptides 1997, 18:1117-1124. 10.1016/S0196-9781(97)00186-1, 9396051.
70. Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond) 1997, 92:467-472.
71. Parkes DG, May CN. ACTH-suppressive and vasodilator actions of adrenomedullin in conscious sheep. J Neuroendocrinol 1995, 7:923-929. 10.1111/j.1365-2826.1995.tb00737.x, 8745270.
72. Vari RC, Adkins SD, Samson WK. Renal effects of adrenomedullin in the rat. Proc Soc Exp Biol Med 1996, 211:178-183.
73. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Burnett JC. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996, 97:2370-2376. 10.1172/JCI118680, 507318, 8636418.
74. Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996, 81:180-183. 10.1210/jc.81.1.180, 8550749.
75. Jougasaki M, Wei CM, McKinley LJ, Burnett JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92:286-289.
76. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 1997, 95:1214-1221.
77. Parkes DG, May CN. Direct cardiac and vascular actions of adrenomedullin in conscious sheep. Br J Pharmacol 1997, 120:1179-1185. 10.1038/sj.bjp.0701034, 1564583, 9134233.
78. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007, 49:1525-1532. 10.1016/j.jacc.2006.12.038, 17418290.
79. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007, 115:2103-2110. 10.1161/CIRCULATIONAHA.106.685503, 17420344.
80. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE, Ng LL. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008, 14:739-745. 10.1016/j.cardfail.2008.07.231, 18995178.
81. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369. 10.1161/01.CIR.0000053730.47739.3C, 12551853.
82. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med 2003, 70:634-640. 10.3949/ccjm.70.7.634, 12882386.
83. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
84. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002, 105:570-575. 10.1161/hc0502.103348, 11827921.
85. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000, 101:1785-1791.
86. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919. 10.1161/01.CIR.0000029802.88087.5E, 12186793.
87. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404. 10.1161/01.CIR.0000052617.91920.FD, 12551862.
88. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28. 10.1056/NEJMoa042378, 15635109.
89. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006, 47:962-968. 10.1016/j.jacc.2005.10.055, 16516078.
90. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997, 96:778-784.
91. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Naruse H, Tanaka I, Nomura M, Hishida H, Ozaki Y. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010, 210:220-5. 10.1016/j.atherosclerosis.2009.10.033, 19945702.
92. de Servi S, Mazzone A, Ricevuti G, Mazzucchelli I, Fossati G, Angoli L, Valentini P, Boschetti E, Specchia G. Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. Am J Cardiol 1996, 78:564-568. 10.1016/S0002-9149(96)00367-0, 8806345.
93. Dinerman JL, Mehta JL, Saldeen TG, Emerson S, Wallin R, Davda R, Davidson A. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990, 15:1559-1563. 10.1016/0735-1097(90)92826-N, 2345235.
94. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5-12. 10.1056/NEJMoa012295, 12097534.
95. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984, 310:1137-1140.
96. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106:2894-2900. 10.1161/01.CIR.0000042674.89762.20, 12460868.
97. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, Tommasi M, Rebuzzi AG, Maseri A. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996, 27:611-616. 10.1016/0735-1097(95)00524-2, 8606272.
98. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445. 10.1161/01.CIR.0000090690.67322.51, 12952835.
99. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007, 93:826-831. 10.1136/hrt.2006.091041, 17194712.
100. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007, 49:1993-2000. 10.1016/j.jacc.2007.02.040, 17512353.
101. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142. 10.1001/jama.286.17.2136, 11694155.
102. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165. 10.1016/j.jacc.2007.03.033, 17616301.
103. Laursen LS, Overgaard MT, Nielsen CG, Boldt HB, Hopmann KH, Conover CA, Sottrup-Jensen L, Giudice LC, Oxvig C. Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis. Biochem J 2002, 367:31-40. 10.1042/BJ20020831, 1222882, 12241545.
104. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001, 345:1022-1029. 10.1056/NEJMoa003147, 11586954.
105. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, Pulkki K. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003, 108:1924-1926. 10.1161/01.CIR.0000096054.18485.07, 14530192.
106. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000, 86:125-130.
107. Beaudeux JL, Burc L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E, Chapman MJ. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003, 23:e7-10. 10.1161/01.ATV.0000047448.76485.B8, 12524241.
108. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, Squire IB. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008,
109. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28:711-718. 10.1093/eurheartj/ehm003, 2202923, 17339265.
110. Dhillon OS, Khan SQ, Narayan HK, Ng KH, Mohammed N, Quinn PA, Squire IB, Davies JE, Ng LL. Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond) 2009, 118:249-57. 10.1042/CS20090226, 19583569.
111. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008, 10:133-139. 10.1016/j.ejheart.2007.12.009, 2635532, 18234553.
112. Steinhart B, Thorpe KE, Bayoumi AM, Moe G, Januzzi JL, Mazer CD. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009, 54:1515-1521. 10.1016/j.jacc.2009.05.065, 19815122.
113. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-b-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55:645-653. 10.1016/j.jacc.2009.08.078, 20170790.
114. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760-1763. 10.1161/01.CIR.0000015464.18023.0A, 11956114.